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SUMMARY STATEMENT 42 
Choroidal neovascularization is a rare cause of visual loss in patients with Best disease. Its optimal 43 
management is unknown. We highlight novel clinical features of disease and present outcome data 44 
suggesting that a better outcome might be obtained with anti-VEGF therapy. 45 
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Functional and Anatomical Outcomes of Choroidal Neovascularisation 51 
complicating BEST1 related retinopathy 52 
Abstract 53 
Purpose: 54 
To describe the presenting features and functional outcomes in a series of patients with choroidal 55 
neovascularization (CNVM) complicating BEST1 related retinopathy (Best Disease, BD and Autosomal 56 
Recessive Bestrophinopathy, ARB). 57 
Methods: 58 
Retrospective review of consecutive cases at a tertiary care eye hospital. Patients were identified 59 
retrospectively over an 11-year period. Records were reviewed to extract demographic, as well as 60 
functional and anatomical outcome data.    61 
Results 62 
14 eyes of 12 patients were identified (11 BD, 1 ARB). Median follow up was 2.8 years (range 0.8 to 63 
6). The median age at CNVM discovery was 15.5 years (range 6 to 72). CNVM were active early in the 64 
disease course prior to vitelliruption. Seven eyes were treated with intravitreal bevacizumab, 7 eyes 65 
were monitored by observation alone. On average patients required a single treatment (median = 1, 66 
range 1-10). The median gain in visual acuity (VA) was greater in the treated versus the observed 67 
group - 0.46 v 0.17 decimalised units of Snellen Acuity respectively (p<0.05 Mann-Whitney U test). 68 
Although a significant reduction in central macular thickness (CMT) was evident in both groups, 69 
150m (treated) and 104m (observed), active treatment was not associated with greater thinning 70 
than observation (p>0.05 Mann-Whitney U test).  71 
Conclusions 72 
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There is a high rate of spontaneous recovery of BEST1-related CNVM, and overall we observed a gain 73 
in VA associated with a reduction in CMT. Active treatment, here with intravitreal bevacizumab, is 74 
associated with better functional outcomes than observation alone. 75 
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Introduction 76 
The bestrophinopathies are a spectrum of inherited retinal dystrophies that result from mutation of 77 
the BEST1 gene. The commonest presentation within this group is Best Disease (BD; Vitelliform 78 
Macular Dystrophy; OMIM 153700), a macular dystrophy characterised by bilateral accumulation of 79 
subretinal yellow material with later eruption into the photoreceptor layer and symptomatic 80 
reduction in vision. This form of the disease is most commonly associated with heterozygous 81 
missense mutations usually within the first half of the BEST1 gene.1, 2 BD is almost always associated 82 
with a reduced light rise of the electrooculogram (EOG).33 The full-field electroretinogram (ffERG) is 83 
normal. In contrast, autosomal recessive bestrophinopathy (ARB; OMIM 611809) associated with bi-84 
allelic BEST1 variants results in a more widespread retinal disease with multifocal accumulation of 85 
subretinal deposit, and abnormalities of the ffERG in addition to a reduced EOG light rise.4  86 
In both BD and ARB, central visual acuity may be affected at any stage, although this usually is 87 
associated with either intraretinal fluid (IRF) accumulation, disruption of the photoreceptor layer 88 
during the vitelliruptive stage of dominant disease, or later atrophy. Rarely, visual decline may be 89 
the result of choroidal neovascular membrane (CNVM) formation. Whilst there are a few case 90 
reports and small series suggesting that CNVM can be successfully treated with intravitreal injections 91 
of recombinant antibodies directed against vascular endothelial growth factor (VEGF) (Ranibizumab, 92 
Bevacizumab), there is no evidence to suggest that outcomes are better than conservative 93 
management (observation alone).5-8 Here we report our clinical experience with a cohort of patients 94 
with BD and ARB, whose disease has been complicated by CNVM.  95 
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Methods 98 
A retrospective review of the electronic patient record system at Moorfields Eye Hospital was 99 
performed with the search terms ‘Best disease’, ‘recessive bestrophinopathy’, ‘choroidal 100 
neovascularisation’ and ‘haemorrhage’ covering the time period between 2003 and 2015. The 101 
hospital notes were then reviewed both to confirm the diagnosis and document the clinical findings. 102 
Only patients with active CNVM were included. CNVM were deemed active if there were two of the 103 
following features were present – acute visual deterioration, retinal haemorrhage or exudate, 104 
intraretinal fluid, irregular pigment epithelial detachment or evidence of neovascularisation with 105 
fluorescein angiography. Presumed inactive CNVM were diagnosed primarily on the basis of 106 
subretinal fibrosis and excluded from this study. Patient demographics (including sex and age at 107 
CNVM diagnosis) and symptoms were noted. Snellen visual acuity recorded in the clinic was 108 
converted into a decimalised value for subsequent analysis. Retinal anatomy was documented with 109 
colour fundus photography using a Topcon TRC 50IA retinal camera (Topcon Corporation, Tokyo, 110 
Japan) and optical coherence tomography (OCT) using the Spectralis SD-OCT (Heidelberg 111 
Engineering, Heidelberg, Germany), with both line and volume scans available for interpretation. 112 
Fundus autofluorescence (FAF) images were acquired using the AF mode of the Spectralis SD-OCT 113 
using either the 30 or 55 degree lenses. Fundus fluorescein angiography (FFA) was performed using 114 
either the Topcon fundus camera or the Spectralis HRA systems.  115 
In order to estimate the period prevalence of CNVM in BEST1 related eye disease we reviewed 116 
retinal images of patients’ known to harbour BEST1 mutations attending between 1.1.2010 and 117 
1.1.2015. Only patients with active disease (as defined above) were included. Numerical data are 118 
described using median values and interquartile ranges, and compared using non-parametric 119 
analysis (Mann-Whitney U test).  120 
This study was approved by the local research ethics committee, and all investigations were 121 
conducted in accordance with the principles of the Declaration of Helsinki. 122 
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Results 123 
Cohort demographics 124 
Twelve patients were identified over the study period with a clinical diagnosis of either BD (n=11) or 125 
ARB (n=1) complicated by active CNVM. Molecular confirmation of the clinical diagnosis was 126 
available in 6/12 cases; genetic testing was not performed in two patients (Table 1).  For the 127 
molecularly unconfirmed cases, confidence in the clinical diagnosis was high as patients presented 128 
with at least two classical features of BD (macular phenotype, reduced EOG, dominant family 129 
history). Six patients (50%) were male. Two patients had bilateral CNVM, thus data from 14 eyes of 130 
twelve patients were available for analysis. The follow up period ranged from 0.8 to 6 years.  One 131 
patient was diagnosed with BD as a child but only developed signs of CNVM aged 72 years (Patient 132 
4). The median age at CNVM discovery was 15.5 years (IQR 13 years). For the two patients with 133 
bilateral disease, sequential involvement of the fellow eye was observed within 4 years. Figure 1 134 
shows images from the fellow eye of patient 8 to illustrate the natural history of BD uncomplicated 135 
by CNVM, for comparison with subsequent figures (Fig. 2-5), which show illustrative images from 136 
Patients 2 and 9; salient features will be discussed in the Results and Discussion below.  137 
Premorbid and presenting clinical characteristics  138 
For 11/14 eyes the acuity prior to CNVM discovery was known and documented to be normal in 9/11 139 
(median = 20/20, IQR = 0). 3/14 eyes presented with active disease, consequently the prior acuity 140 
was unknown. For 2/11 the baseline visual acuity was already reduced. Patient 4 presented aged 72 141 
with advanced BD; her results will be presented separately. Patient 2 had suffered with prior 142 
neovascular disease in the same eye more than two yearspreviously, accounting for her reduced 143 
presenting vision. Visual acuity in the fellow eye at the time of CNVM discovery was similar to the 144 
pre-CNVM acuity in affected eyes (median 20/20, IQR = 0), strongly suggesting that both eyes were 145 
at a similar stage of disease and that neovascularisation occurs relatively early in the disease course. 146 
The median visual acuity at CNVM discovery was 20/60 (0.33, IQR = 0.17), overall representing a 147 
moderate reduction from baseline, although for individual patients this varied significantly (range = 148 
20/20 to 20/400) (Table 1). The presenting acuity did not appear to be inversely correlated with 149 
acuity in the fellow eye. Patient 4 began with acuity of 20/120 right and 20/80 left. Her vision then 150 
fell to 20/200 in the right eye as the CNVM became active; 5 years later subretinal scarring resulted 151 
in a final acuity of 20/1200. The fellow eye remained at 20/80 throughout the follow up period.  152 
Where SD-OCT scans were available prior to CNVM detection (n= 9), pre-existing SRF was present in 153 
seven cases (example shown in Fig. 2A). IRF however was never observed. All patients reported a 154 
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symptomatic reduction in their central vision (n=14 eyes). In all cases haemorrhage was noted at 155 
some point in the disease course, and was always subretinal in location and found either inside the 156 
boundaries of the yellow vitelliform lesion or at its border. Four patients presented in the month 157 
preceding hemorrhage detection with new symptoms of dysmorphopsia. In these cases FFA showed 158 
no evidence of vascular leakage. It is however possible that they had active neovascular disease at 159 
this time that evaded detection with conventional imaging techniques.   160 
Imaging in active disease 161 
Fundus fluorescein angiography (FFA) was requested in 9/14 cases and available for review. In a 162 
minority (3/9) late leakage of undetermined origin was evident. The majority (6/9) however 163 
demonstrated staining of the hyperfluorescent subretinal deposit thus masking any subtle changes 164 
being further characterised. Indocyanine green angiography performed in one case (Patient 12) 165 
showed only masking.   166 
Optical coherence tomographic imaging of the retina-RPE-choroidal interface was available for all 167 
cases (14 eyes) and demonstrated abnormalities in the four cases that were symptomatic prior to 168 
haemorrhage being visualised. The earliest visible changes were at the level of the RPE, with 169 
separation from Bruch’s membrane due to presumed CNVM (see Figures 2b, 3b, 4e, 5a). The 170 
maximal site of RPE elevation was always found in the lower half of the macular lesion (n=14), and 171 
often no disturbance was seen in the superior half (see Figure 3A and 3B). Other OCT features 172 
observed in patients with CNVM were subretinal fluid (SRF) (n=14), new IRF (n=12), discontinuity in 173 
Bruch’s membrane (n=7), areas of choroidal excavation (n=4) and presumed photoreceptor outer 174 
segment delamination (n=1). At the final follow up visit SRF was still present in all eyes.  175 
Fundus autofluorescence imaging was used to identify subretinal deposition, which was 176 
hyperautofluorescent in all cases. Areas with SRF exhibited reduced autofluorescence and when 177 
haemorrhage was present the normal autofluorescence was masked to a greater extent than by fluid 178 
alone. Inactive CNVM associated with fibrosis and organising haemorrhage that had become 179 
depigmented may be mistaken for yellow subretinal deposit seen in typical BD. Autofluorescence 180 
was useful in differentiating deposit (hyperautofluorescent) from fibrosis and scarring which are 181 
both hypoautofluorescent (Figures 4B and 5D,E show autofluorescence images from the same eye 182 
before and after CNV development). Rupture of the RPE resulting from vertical extension of a CNVM 183 
was again associated with reduced autofluorescence. 184 
Outcomes 185 
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As all the patients identified presented with active CNVM after 2009, treatment with intravitreal 186 
bevacizumab (1.25mg/0.05ml) was potentially available to all cases.  Seven eyes in this series 187 
received active treatment. Three of these patients had neovascular disease in their better seeing 188 
eye, as fellow eyes were affected by amblyopia (n=2) or prior CNVM (n=2); factors which may have 189 
influenced the decision to use an anti-VEGF agent. The majority (5/7) of treated patients were over 190 
the age of 18, perhaps reflecting the ease of administering intravitreal therapy in an adult versus 191 
paediatric population where sedation or general anaesthesia may be required. Of the seven treated 192 
patients, four had a single injection, one received a second injection, one (Patient 12) had a 193 
predetermined course of three ‘loading’ injections and one (Patient 8) received ten intravitreal 194 
treatments. The multiple injections required by Patient 8 may represent partial response to this 195 
therapy, membrane recurrence, or the inability to correctly identify an endpoint for treatment. 196 
Patient 2 was also thought to have developed late CNVM recurrence surrounding a previously 197 
inactive disciform scar.  198 
As a group, the median change in vision after presenting with an active CNVM until the final follow 199 
up visit was a gain of 0.34 decimalised Snellen lines (IQR 0.48), equivalent to a change from 20/60 200 
(median presenting acuity) to 20/32. The treated eyes had a median gain in vision of 0.46 (IQR = 201 
0.32), whilst eyes monitored by observation alone also gained vision, recording a more modest 202 
increase of 0.17 decimalised Snellen acuity (median gain, IQR = 0.39). This difference was found to 203 
be significant (Mann-Whitney U test, p < 0.05).  204 
Central retinal thickening was evident in all cases at CNVM discovery, with a median central 1mm 205 
macular thickness of 561μm (IQR = 160) (observed) compared to 411μm (IQR = 441) (treated) 206 
(Mann-Whitney U test, p > 0.05). At final follow up this had reduced to a similar extent in both the 207 
groups; 150μm (IQR = 41) (observed) and 104μm (IQR = 240) (treated) (Mann-Whitney U test, p > 208 
0.05).  209 
During a five-year interval from 2010-2015, 107 molecularly confirmed cases of BEST1 related eye 210 
disease were recorded at Moorfields Eye Hospital. Molecular genetic testing is offered as an adjunct 211 
to the clinical examination, particularly if there is any clinical doubt regarding diagnosis. Testing 212 
would not have been offered, or accepted, in a further unquantifiable cohort of patients. Six of these 213 
patients later presented with active CNVM, suggesting a minimum prevalence of 5.6% (6/107) during 214 
this period. 215 
 216 
217 
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Discussion 218 
Choroidal neovascularisation is thought to be a rare complication of BEST1 related retinopathy; 219 
however the exact prevalence is currently unknown. 9-13 In this study we have identified 14 eyes from 220 
twelve patients who have presented with active choroidal neovascular disease associated with 221 
either BD or ARB. Within our own genetic database, this equates to a period prevalence of 5.6%, 222 
significantly higher than one may have expected. In the majority of cases, neovascularisation 223 
occurred early in the disease course, when visual acuity would otherwise be unaffected. The natural 224 
history of these membranes appears to follow a more benign course than those associated with age-225 
related macular degeneration (ARMD), with a median gain of 0.34 decimalised units of Snellen acuity 226 
after resolution. Treatment with intraviteal bevacizumab (n=7) was associated with greater visual 227 
gain when compared to observation alone (n=7, Mann-Whitney U test p <0.05). 228 
Diagnosing CNVM in the context of BEST1 related retinopathy is complicated by the presence of pre-229 
existing subretinal deposit, which stains during FFA. We suggest additional features that may aid 230 
diagnosis or at least heighten clinical suspicion. Typical disease uncomplicated by neovascularisation 231 
is associated with subretinal deposit that organises over time, and often is later accompanied by SRF 232 
(Figure 1). The residual deposit becomes distributed in a pattern that is primarily influenced by 233 
gravity resulting in a predominantly inferior accumulation (the pseudohypopyon stage). Persistence 234 
of the dense deposit inferiorly may result in a greater insult to the inferior retina-RPE complex than 235 
that in the superior macula.  In keeping with this hypothesis, whenever we were able to identify the 236 
neovascular complex it was always sited within the inferior half of the vitelliform lesion (Figures 2-5). 237 
In no cases were membranes seen to arise from the superior half of the lesion. In most cases the 238 
CNVM develop relatively early in the disease course, prior to vitelliruption, as normal acuity had 239 
been recorded within the past seven months in 82% (9/11 eyes), suggesting normal central 240 
photoreceptor function.  As the membranes grow, they breach Bruch’s membrane and distort the 241 
RPE resulting in localised detachments (Figures 2b, 3b, 4e, 5a). In the absence of CNVM the RPE 242 
should otherwise appear flat and apposed to Bruch’s membrane (Figure 1). Bruch’s membrane is 243 
usually not visible on OCT. RPE detachment results in the two structures now being separately 244 
resolved (Figures 2b, 3b, 4e), which are presumed to be the RPE and Bruch’s membrane. Type 1 245 
membranes sit below the RPE and in the earliest stages are not perfused.14 As they mature and 246 
support a blood flow they may leak, just as an occult CNVM associated with AMD would. Serous 247 
leakage into the sub-RPE compartment may result in fibrosis and RPE hyperplasia without the 248 
appearance of frank haemorrhage.15 This may account for the fibrotic appearance of the macula in 249 
some patients with BD rather than the better defined atrophic maculopathy. If this is the case, 250 
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CNVM may be a more common complication of BD as both atrophy and fibrosis were recognised as 251 
endpoints for this disease when it was originally classified.  Should the CNVM breach the RPE 252 
becoming a type 2 membrane it can grow within the vitelliform space.14 Contact with the subretinal 253 
surface provides a scaffold for progression, with or without duplication of the RPE. The membrane 254 
may bleed into the subretinal as well as sub RPE cavity or leak serous fluid. The presence of 255 
definitively new fluid would be hard to detect as SRF is a typical feature of BD in the absence of 256 
CNVM, but CNVM activity may additionally result in IRF, not typically seen in BD (Figures 2c, 3a) but 257 
present in ARB (Figure 6). As the CNVM contracts it may exert tractional forces on the subretinal 258 
surface, and as there is sufficient space within the fluid filled cavity we can occasionally observe a 259 
presumed detachment/delamination of the photoreceptor outer segments (present in Figure 3c). 260 
Abnormal neovascular networks may also form anastomoses between the retinal and choroidal 261 
circulations (Type 3 membranes).  262 
It is likely that a recently developed imaging technique, OCT angiography (OCTA), will offer the best 263 
method of visualising well perfused CNVMs, as it is minimally influenced by the presence of 264 
subretinal deposit unlike FFA (personal observation, unpublished data). It will be interesting to see in 265 
these cases if CNVM anatomy as defined by OCTA correlates to visual outcome, as this may help to 266 
provide further prognostic information. If it becomes evident that specific subtypes of CNVM are 267 
associated with a better prognosis, or are more responsive to treatment, as is the case in ARMD, this 268 
additional information will be particularly helpful in the management of paediatric patients, where 269 
organising treatment is not as straight forward as for adults.15  270 
Age related CNVM are associated with diffuse thickening of the RPE basal membrane (basal laminar 271 
deposit) and secondary dystrophic calcification, whilst pediatric CNVM are not.16 “Juvenile” 272 
membranes are thought to result from a more localised abnormality with a solitary site of subretinal 273 
vascular invasion rather than the multifocal vascular breaches that occur with age.17 This is in 274 
keeping with the natural history and prognosis for these membranes being better than for those 275 
which occur in ARMD, and may explain why spontaneous regression is reported to be very common 276 
in pediatric CNVM.18, 19 The initial report of visual outcomes in BD complicated by CNVM monitored 277 
by observation alone suggested that recovery could be expected in the majority of cases (10/11 eyes 278 
in the initial series) with 9/11 eyes recording a final acuity of better than 20/50.9 Smaller, more focal 279 
CNVM may also explain their sensitivity to treatment with anti-VEGF agents, as single treatments are 280 
often sufficient.5-8, 20 Rishi et al have most recently reported their experience treating pediatric 281 
CNVM and present data on four patients with BD who were followed up for more than one week.21 282 
The 3 patients who received treatment showed either an improvement (from 20/200 to 20/120 and 283 
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20/20) or stabilisation of vision (at 20/30). One patient with inactive disease was followed by 284 
observation only and his vision spontaneously improved (20/200 to 20/30), again highlighting the 285 
good visual outcome that may be seen with spontaneous regression of CNV in children. Pediatric 286 
CNVM may also complicate structural abnormalities (angioid streaks, choroidal osteoma, optic nerve 287 
head drusen, trauma and less commonly myopia), intraocular inflammation (presumed ocular 288 
histoplasmosis syndrome, mutifocal choroiditis, toxoplasmosis) or be idiopathic. 21 CNVM are also a 289 
rare complication of other childhood-onset forms of inherited retinal disease and have been 290 
reported to occur with choroideremia,22 North Carolina macular dystrophy,23 and Stargardt 291 
disease.24 292 
The visual outcomes presented, especially for the untreated group are perhaps surprisingly good, 293 
again highlighting the difference with ARMD. In two cases only one treatment was required, 294 
suggesting that the membranes are exquisitely sensitive to anti-VEGF or that the disease is 295 
monophasic. Endpoints that are valid when treating CNVM associated with ARMD may not be 296 
helpful for membranes occurring in the context of BD. We suggest that as SRF can be expected to 297 
both pre- and post-date CNVM discovery/activity its usefulness as a biomarker for choroidal 298 
neovascularisation is limited. Similarly reliance on automated measurements of central retinal 299 
thickness from SD-OCT scans may be unwise, as SRF will be overrepresented within this 300 
measurement. This may account for the difference in anatomical and functional outcomes that were 301 
recorded here, as patients with typical CNVM recorded better visual outcomes if they received 302 
treatment (p=0.03), however their central retinal thickness measurements did not mirror these 303 
changes. A more accurate use of SD-OCT data may involve segmentation of the retinal sub-layers, 304 
recording measurements between the internal limiting membrane (ILM) and ellipsoid zone (EZ), 305 
perhaps more representative of IRF. This parameter may correlate better with changes in vision, 306 
although our experience of treating patients with ARMD may suggest that this will not always be the 307 
case. For ARB even this technique may have limited utility, as IRF is the norm. IRF may also be seen 308 
in a minority of cases of end stage BD, so in the setting of significant RPE disease both SRF and IRF 309 
may be expected, even in the absence of CNVM, thereby complicating diagnosis. 310 
Surprisingly in one case, haemorrhage secondary to the neovascular membrane did not occur until 311 
after the age of 70, whist all other cases were detected under the age of 25 years of age. A number 312 
of explanations are possible. Firstly, CNVM occurrence may be independent of disease stage, 313 
although in this series 9/14 eyes recorded a normal acuity within the past seven months, suggesting 314 
that the majority of photoreceptors were unaffected consistent with the earliest stages of disease. 315 
Secondly, this patient may have suffered with prior neovascular complications, and the detected 316 
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episode in fact represents a recurrence of disease activity. Finally, the CNVM identified might have 317 
occurred independent of the BEST1 mutation, relating instead to ARMD. As monogenic disorders can 318 
show phenotypic overlap with ARMD, and mutations in BEST1 may be non-penetrant and variably 319 
expressed, it is also quite possible that BEST1-related retinopathy may masquerade as either 320 
neovascular or non-neovascular ARMD.  321 
Lastly, it is important to highlight that the retrospective nature of this study carries with it inherent 322 
limitations. Under-ascertainment is likely to have occurred, most evident due to the lack of cases 323 
identified prior to 2009. Molecular confirmation of the diagnosis was not available for 8/14 cases, 324 
although all did report a dominant family history consistent with BD, and in two cases a reduced 325 
Arden ratio was additionally recorded. Absence of randomisation when selecting the intervention 326 
may have provided a bias towards treating the more severe cases, although by chance the 327 
presenting visual acuities appear to be well matched between the two groups (median = 0.32 v 0.34, 328 
decimalsied Snellen). Visual acuity data may also have been influenced by uncorrected refractive 329 
error which was not controlled for, but perhaps equally distributed throughout the two groups. 330 
Finally, the wide variation in duration of follow up may influence the final acuity, as the natural 331 
history of BD is progression to macular atrophy. No such trend was apparent however. 332 
In summary, we present the largest case series to date of CNVM complicating BD and ARB. In this 333 
non-randomised retrospective series we have identified that these membranes have a high rate of 334 
spontaneous resolution, and additional visual gains may be obtained with the use of intravitreal anti-335 
VEGF therapy. In the vast majority of cases CNVM should be considered as a relatively early potential 336 
complication of BD. Occasionally this rare complication may recur. We also highlight novel OCT 337 
features seen in both early and late neovascular disease that will facilitate identification of these 338 
lesions. Lastly, we suggest that CNVM may be a potentially under-recognised complication of BEST1-339 
related retinopathy, and the advent of novel imaging techniques may help to prove this.  340 
 341 
342 
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Tables 421 
Table 1. Summary of patient characteristics.  422 
Patient. ID. BEST1 variant Follow 
up 
(years) 
Eye 
with 
CNVM 
Age at 
CNVM 
discovery 
Treatment 
given?  
(Number) 
Pre-CNVM 
VA if known 
(decimalised 
Snellen) 
Presentation  
VA 
(decimalised 
Snellen) 
Final Visit 
VA 
(decimalised 
Snellen) 
1 29774  p.Arg356X ; 
p.Ile201Thr 
5 OS 12 No  1 0.4 0.95 
2 31575  p.Arg218Cys  
 
1.5 OD 9 Yes (1) 0.43
* 
 
0.22 0.5 
3 1264937 Not known 3 OD 10 No  1 0.05 0.05 
4 12171  p.Phe298Val 6 OD 72 No 0.14 0.1 0.016 
5 1597719 Not known 2.5 OD 6 No  Not 
known 
0.32  0.66  
3 OS 6 0.2  0.25  
6 31286  Not known 3 OS 13 No  1  0.46 0.63 
7 29283  p.Ser16Phe 1.5 OS 20 Yes (1) Not 
known 
0.34 0.8 
8 29668  p.Arg105Gly 4 (6) OD 24 Yes (10) 1 0.66 1
^
 (0.66)
#
 
9 29781  p.Phe298Val  
 
2 OD 28 Yes (2) 1 0.25,  1  
5 OS 25 No 1 0.1 0.66 
10 1787207  Not known 1 OD 18 Yes (1) 1 0.34 1 
11 1799554 Not known 0.8 OD 10 Yes (1) 1 0.19  0.8 
12 2172661 Not known 0.8 OD 19 Yes (3) 1 0.25 1 
 423 
*
prior CNVM in this eye hence reduced baseline vision 424 
^
VA when considered stable after 4
th
 and 8
th
 treatment 425 
 
#
VA at final follow up 6 years later 426 
427 
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Figure Legends 428 
Figure 1. Serial images one year apart from the left eye of Patient 8, showing organisation of the 429 
pseudo-vitelliform lesion. Left-hand panels show infrared reflectance images, and right-hand panels 430 
show corresponding spectral domain OCT scans taken in the same location. A, OCT image shows the 431 
subretinal deposit or fluid lies in a mound below a largely intact, but irregular outer retinal ellipsoid 432 
line. B, Image taken one year later shows greater irregularity of the ellipsoid line with some areas of 433 
focal hyperreflectivity in the outer nuclear layer.. C, Further images taken one year later show 434 
approximation between retina and RPE close to the location of the previous hyperreflective areas, 435 
likely to be the area of subsequent scarring. At all time points, the RPE lies flat against Bruch’s 436 
membrane (itself not visible) with no signs of CNVM. 437 
Figure 2. Images from the right eye of Patient 9. A, Prior to CNVM development, the RPE lies flat with 438 
a shallow foveal detachment. B, As the CNVM develops, an irregular RPE elevation becomes evident 439 
(white arrow), beneath which Bruch’s membrane is now visible. C, Signs of active CNVM leakage 440 
manifest, with intraretinal fluid, continued presence of subretinal fluid and sub-RPE hemorrhage. 441 
This was treated with intravitreal bevacizumab (two injections). D and E, OCT scans at a later time 442 
point showing chronic subretinal fluid superiorly (D) and atrophic scarring within the lesion (E). 443 
Figure 3. Images from Patient 2 with active neovascular disease in the left eye. A, OCT scan taken 444 
through the superior part of the lesion demonstrates subretinal fluid (between the RPE and the 445 
photoreceptor outer segments), cystic expansion of the ONL so that it merges with the OPL, 446 
highlighting fluid probably accumulating between the ONL ‘proper’ and the axonal component of 447 
this layer (Henle’s layer) with the OPL band representing the dendritic connections between the 448 
photoreceptors and bipolar/horizontal cells. There is also microcystic oedema within the inner 449 
nuclear layer. B, Scanning at a more inferior location identifies a focal hemorrhagic RPE elevation 450 
(arrow), blood within the subretinal space and a small additional bright layer between the subretinal 451 
blood and the photoreceptor outer segments themselves immediately below the ellipsoid zone. C, 452 
OCT scan at a similar location 3 months later. The additional highly reflective layer is now absent.  453 
The subretinal space below now contains a broad zig-zag shaped line possibly consistent with 454 
delaminating photoreceptor outer segments. D, Eight months later the ellipsoid layer is not clearly 455 
visible at this same location. E, Inferiorly, there is a hypertrophic outer retinal scar and persistence of 456 
subretinal fluid. 457 
Figure 4. Images from the left eye of Patient 9 prior to CNVM debvelopment. A, Color fundus 458 
photograph. B, Short wavelength fundus autofluorescence (FAF) image showing 459 
hyperautofluorescence of the subretinal deposit. C, Fundus fluorescein angiogram (FFA) at 11 s after 460 
dye injection.  D, FFA at 2 min showing staining of the subretinal deposit without clear evidence of 461 
active leakage. E, OCT image obtained at the same visit.  462 
Figure 5. Subsequent images from the left eye of Patient 9. A, B, C, OCT scans taken 2 months later 463 
when the patient developed further symptoms, showing elevation of the RPE with possible breach of 464 
this layer (arrow in A), haemorrhage and inferiorly disruption of the photoreceptor outer segments, 465 
possibly resulting from subretinal fluid. D, FAF image shows that this is associated with loss of short 466 
wavelength autofluorescence within the lesion and a reduction in autofluorescence inferior to the 467 
lesion (associated with photoreceptor disruption). This eye did not undergo treatment. E, FAF image 468 
4 years later showing that the inferior hypoautofluorescence is maintained. F, OCT scan at the same 469 
location suggests some restoration in outer retinal architecture. G, OCT through the lesion at the 470 
same visit. 471 
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Figure 6. Images from a patient diagnosed with ARB showing subretinal and intraretinal fluid in the 472 
absence of CNVM. A and B, OCT scans through the fovea of right and left eye respectively. C and D, 473 
OCT scans through locations inferior to the fovea from right and left eye respectively. 474 
475 
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